#Ocrelizumab – How Ocrelizumab Works

admin avatar

by admin |

Share this article:

Share article via email

news-33

Ocrelizumab, an anti-CD20 monoclonal antibody, targets mature B-cells. Almost 95% of the B-cell population has these antigenic epitopes after maturation and does not shed them, which is what makes it a potent marker for therapeutic purposes (cancer being a very common area of interest in this regard).

Read more about Ocrelizumab here: http://bit.ly/1JUBLqj

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here